Michael Zile

Author PubWeight™ 14.43^‹?›

Top papers

Rank	Title	Journal	Year	PubWeight™‹?›
1	The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial.	Lancet	2012	3.66
2	A comparative analysis of the results from 4 trials of beta-blocker therapy for heart failure: BEST, CIBIS-II, MERIT-HF, and COPERNICUS.	J Card Fail	2003	1.60
3	Renin-angiotensin inhibition in diastolic heart failure and chronic kidney disease.	Am J Med	2013	1.03
4	Chronic ambulatory intracardiac pressures and future heart failure events.	Circ Heart Fail	2010	0.90
5	Baseline plasma NT-proBNP and clinical characteristics: results from the irbesartan in heart failure with preserved ejection fraction trial.	J Card Fail	2009	0.89
6	The irbesartan in heart failure with preserved systolic function (I-PRESERVE) trial: rationale and design.	J Card Fail	2005	0.88
7	Myosin cross-bridge dynamics in patients with hypertension and concentric left ventricular remodeling.	Circ Heart Fail	2012	0.86
8	A prediction model for sudden cardiac death in patients with heart failure and preserved ejection fraction.	Eur J Heart Fail	2014	0.84
9	Continuous hemodynamic monitoring in patients with mild to moderate heart failure: results of The Reducing Decompensation Events Utilizing Intracardiac Pressures in Patients With Chronic Heart Failure (REDUCEhf) trial.	Congest Heart Fail	2011	0.82
10	Fabrication and characterization of bio-engineered cardiac pseudo tissues.	Biofabrication	2009	0.81
11	Left ventricular diastolic function and exercise capacity in community-dwelling adults ≥65 years of age without heart failure.	Am J Cardiol	2011	0.80
12	Combined immunoelectron microscopic and computer-assisted image analyses to detect advanced glycation end-products in human myocardium.	Histochem Cell Biol	2010	0.77
13	Rationale and design: the VALsartan In Diastolic Dysfunction (VALIDD) Trial: evolving the management of diastolic dysfunction in hypertension.	Am Heart J	2006	0.77